Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Whalewatcher1on Dec 28, 2021 4:29pm
71 Views
Post# 34266021

RE:RE:Question for Whalewatcher

RE:RE:Question for WhalewatcherC10H12N2, my point is simply that the company is currently publicly traded on CSE and OTC. When uplist to Nasdaq, you don't set a new price irrespective of past trading. Share price is based on price of last trade. I.e. today shares closed at $3.26 on OTC, if Nasdaq listing was effective tomorrow then Nasdaq price would be based on $3.26. if company was private, then yes, can set price at differeltn levels which is the example you keep coming back to. Not sure how you think this will open at around $9, no rationale for that. Simply go look at the last 50 companies traded in Canada that then uplisted from OTC to Nasdaq, that it the presidence.

Also, dont be surprised to find out that Nasdaq will come back and also require sizeable capital raise to support 12+ months of development based on guidance of studies to be completed and historical burn.  Thus large raise at $5M valuation which will be incredibly dilutive 

LETS SEE WHAT HAPPENS IN JANUARY . . . . 

<< Previous
Bullboard Posts
Next >>